THE PHAGE, Inc.
PrivateLast Round
Series A
Oct 9, 2026
Est. Valuation
$10.83M
Total Funding Raised
$3.6M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
THE PHAGE, Inc. operates in Healthcare & Life Sciences and is based in Tokyo. Its latest recorded funding round was a Series A round in October 2026.
THE PHAGE, Inc. is a healthcare technology company that provides personalized blood glucose control solutions through its AI-powered application, Glucose Flight®, and offers R&D support services to the medical and food industries.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Healthcare Analytics, InsurTech
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
THE PHAGE, Inc. Comparables
Compare THE PHAGE, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Health2Sync | 77% | |
| Welby Inc. | 73% | |
| Kakao Corp. | 70% |
For institutional investors. Book with your work email.
THE PHAGE, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 9, 2026 | ||||
| Early Funding | Mar 3, 2026 | ||||
| Series A | Sep 12, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
THE PHAGE, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tokio Marine & Nichido Fire Insurance | Series A |
| Vision Incubate | Series A |
| Genesia Ventures | Series A, Seed |
| ITOCHU Technology Ventures | Series A |
| Mizuho Capital | Series A |
| Fukui Capital Partners | Series A, Early Funding |
| 未来創造キャピタル株式会社 | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 9, 2026
$4M round led by ITOCHU Technology Ventures.
- Mar 3, 2026
Raised capital led by Fukui Capital Partners.
For institutional investors. Book with your work email.
THE PHAGE, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about THE PHAGE, Inc.'s valuation, stock price, and market status.
Is THE PHAGE, Inc. a public or private company?
THE PHAGE, Inc. is a private company.
What is the current stock price of THE PHAGE, Inc.?
THE PHAGE, Inc. is a private company, so its shares have no public market price. Caplight tracks THE PHAGE, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is THE PHAGE, Inc. worth (valuation)?
THE PHAGE, Inc.'s valuation is estimated at $10.8M based on funding round data.
Can I buy THE PHAGE, Inc. stock?
THE PHAGE, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was THE PHAGE, Inc.'s last funding round?
THE PHAGE, Inc.'s most recent funding round was Series A on October 9, 2026.
Who are the main investors in THE PHAGE, Inc.?
Key investors in THE PHAGE, Inc. include Genesia Ventures, ITOCHU Technology Ventures, Fukui Capital Partners.
Will THE PHAGE, Inc. IPO soon?
No public IPO plans have been announced for THE PHAGE, Inc..
How can I track THE PHAGE, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in THE PHAGE, Inc.'s shares on secondary markets.